Implant Sciences Sells QS-B220 Explosives and Drugs Trace Detector to Major European Airport
Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the sale of its Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector to a major European airport. The QS-B220, which was introduced last year, has been purchased by a growing number of corporations and governments. The QS-B220 is currently undergoing U.S. Transportation Security Administration (TSA) qualification testing for air cargo screening.
"Radiation concerns weigh heavily in the decision processes of European customers. Because our Quantum Sniffers do not use a radioactive source, they become a natural choice for European security equipment purchasers. Our desktop model's intuitive and easy-to-use interface is a strong competitive advantage for our product and proved to be a key factor in the purchase decision," stated Implant Sciences' Global Vice President of Sales and Marketing Darryl Jones.
Threat Detection Systems Market - Global Forecast to 2022
In November of 2011, the European Union banned the use of X-ray technology for security screening purposes in European airports due to radiation risks and concerns.
"Aviation security was a primary target when we developed the QS-B220. We are excited by the attention we are receiving in this important market, and look forward to the continued growth of the list of countries where the system is deployed," added Implant Sciences' President and CEO, Glenn D. Bolduc.
Source : Implant Sciences Corp.
Sep 27 - 28, 2017 - Praha 6, Czech Republic